Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Q3 2022 Results Conference Call November 8, 2022 8:30 AM ET
Company Participants
Warren Huff - Chief Executive Officer
Manmeet Soni - President
Colin Meyer - Chief Innovation Officer
Seemi Khan - Chief Medical Officer
Dawn Bir - Chief Commercial Officer
Conference Call Participants
Yigal Nochomovitz - Citigroup
Madhu Kumar - Goldman Sachs
Yatin Suneja - Guggenheim
Charles Duncan - Cantor Fitzgerald
Carter Gould - Barclays
Annabel Samimy - Stifel
Maurice Raycroft - Jefferies
Operator
Thank you for standing by, and welcome to the Reata Pharmaceuticals Third Quarter 2022 Financial Results and Update on Development Programs Conference Call. An audio recording of today's webcast will be available shortly after the call in the Investor section of Reata's website at reatapharma.com.
Before the Company proceeds with its remarks, please note the forward-looking statements disclosure in the Company's press release. There are many factors that could cause results to differ from expectations, including those noted in the Company's SEC filings.
On today's conference call, non-GAAP financial measures will be used to help investors understand the business performance. These non-GAAP financial measures are reconciled with comparable GAAP financial measures in the Reata's earnings release and presentation from today, which again can be found in Reata's website.
Today's statements are not guarantees of future outcomes. Please also note that any comments made on today's call apply only as of today, November 8, 2022, and may no longer be accurate at the time of any webcast replay or transcript rereading. Following the prepared remarks, we will open the call up for questions. [Operator Instructions]
We are joined today by Warren Huff, Reata's Chief Executive Officer; Manmeet Soni, President; Colin Meyer, Chief Innovation Officer; Seemi Khan, Chief Medical Officer; and Dawn Bir, Chief Commercial Officer.
At this time, I would like to turn the call over to Warren Huff.
Warren Huff
Good morning, everyone. We thank you for joining us today for our quarterly update. I'll start on Slide 4. Since Reata's founding in 2002, our scientific mission has been to identify, develop and commercialize therapeutics with novel mechanisms of action for the treatment of severe life-threatening diseases that have few or no approved therapies. Toward that goal, we're developing omaveloxolone, or omav, a small molecule activator or Nrf2 for the treatment of patients with Friedreich's Ataxia or FA.
FA is a relentlessly progressive and debilitating neuromuscular disorder, which affects approximately 4,000 diagnosed patients in the United States. There are no approved therapies for these patients and FA patients typically become dependent on walkers and then wheelchairs in their mid-20s and unfortunately, they pass away from the disease in their mid-30s.